Zaharevitz DW - Search Results

1

Zaharevitz DW. Zaharevitz DW. J Cheminform. 2011 Oct 14;3:34. doi: 10.1186/1758-2946-3-34. J Cheminform. 2011. PMID: 22017861 Free PMC article.

2

Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003.

Stone HB, Moulder JE, Coleman CN, Ang KK, Anscher MS, Barcellos-Hoff MH, Dynan WS, Fike JR, Grdina DJ, Greenberger JS, Hauer-Jensen M, Hill RP, Kolesnick RN, Macvittie TJ, Marks C, McBride WH, Metting N, Pellmar T, Purucker M, Robbins ME, Schiestl RH, Seed TM, Tomaszewski JE, Travis EL, Wallner PE, Wolpert M, Zaharevitz D. Stone HB, et al. Radiat Res. 2004 Dec;162(6):711-28. doi: 10.1667/rr3276. Radiat Res. 2004. PMID: 15548121

3

Chem-X and CAMBRIDGE. Comparison of computer generated chemical structures with X-ray crystallographic data.

Nicklaus MC, Milne GW, Zaharevitz D. Nicklaus MC, et al. J Chem Inf Comput Sci. 1993 Jul-Aug;33(4):639-46. doi: 10.1021/ci00014a019. J Chem Inf Comput Sci. 1993. PMID: 8366147

4

Inhibition of CDKs as a therapeutic modality.

Sausville EA, Johnson J, Alley M, Zaharevitz D, Senderowicz AM. Sausville EA, et al. Ann N Y Acad Sci. 2000 Jun;910:207-21; discussion 221-2. doi: 10.1111/j.1749-6632.2000.tb06710.x. Ann N Y Acad Sci. 2000. PMID: 10911915

5

Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.

Cleaveland ES, Zaharevitz DW, Kelley JA, Paull K, Cooney DA, Ford H Jr. Cleaveland ES, et al. Among authors: zaharevitz dw. Biochem Biophys Res Commun. 1996 Jun 25;223(3):654-9. doi: 10.1006/bbrc.1996.0950. Biochem Biophys Res Commun. 1996. PMID: 8687451

6

Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.

Zaharevitz DW, Gussio R, Leost M, Senderowicz AM, Lahusen T, Kunick C, Meijer L, Sausville EA. Zaharevitz DW, et al. Cancer Res. 1999 Jun 1;59(11):2566-9. Cancer Res. 1999. PMID: 10363974

7

Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target.

Sausville EA, Zaharevitz D, Gussio R, Meijer L, Louarn-Leost M, Kunick C, Schultz R, Lahusen T, Headlee D, Stinson S, Arbuck SG, Senderowicz A. Sausville EA, et al. Pharmacol Ther. 1999 May-Jun;82(2-3):285-92. doi: 10.1016/s0163-7258(98)00062-x. Pharmacol Ther. 1999. PMID: 10454206 Review.

8

Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition.

Gussio R, Zaharevitz DW, McGrath CF, Pattabiraman N, Kellogg GE, Schultz C, Link A, Kunick C, Leost M, Meijer L, Sausville EA. Gussio R, et al. Among authors: zaharevitz dw. Anticancer Drug Des. 2000 Feb;15(1):53-66. Anticancer Drug Des. 2000. PMID: 10888036

9

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.

Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA. Johnson JI, et al. Br J Cancer. 2001 May 18;84(10):1424-31. doi: 10.1054/bjoc.2001.1796. Br J Cancer. 2001. PMID: 11355958 Free PMC article.

10

An information-intensive approach to the molecular pharmacology of cancer.

Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Paull KD. Weinstein JN, et al. Among authors: zaharevitz dw. Science. 1997 Jan 17;275(5298):343-9. doi: 10.1126/science.275.5298.343. Science. 1997. PMID: 8994024

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

54 results

Search Page